Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05459753 · ClinicalTrials.gov registry record · NA

Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

A NA study of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Michigan.

Active
Registry status
NA
Development phase
125
Enrollment target
1
Study location

NCT05459753 is a NA study of Parkinson Disease and Progressive Supranuclear Palsy that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 125 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05459753, a NA study of Parkinson Disease and Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by University of Michigan.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
125 participants
Enrollment target
1
Study location

Study Summary

To perform a prospective cohort study with \[(18)F\]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.

Interventions

  • RADIATION (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET
  • RADIATION Dihydrotetrabenazine (DTBZ) PET

Study Locations (1)

Michigan

  • University of Michigan - Michigan Medicine - Ann Arbor

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2022-03-01
Est. Completion 2026-06-30
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT05459753

The ClinicalTrials.gov registry entry for NCT05459753 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET is the first listed.

NCT05459753 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT05459753 about?

NCT05459753 is a clinical study titled "Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)". To perform a prospective cohort study with \[(18)F\]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.

What is the current status of trial NCT05459753?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-03-01. Estimated completion is 2026-06-30.

What conditions does trial NCT05459753 study?

This clinical trial studies the following conditions: Parkinson Disease, Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT05459753?

The interventions under investigation include: (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET (RADIATION), Dihydrotetrabenazine (DTBZ) PET (RADIATION).

Who is sponsoring clinical trial NCT05459753?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05459753 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.